BTI
CRSP icon

Blue Trust Inc’s CRISPR Therapeutics CRSP Stock Holding History

Blue Trust Inc’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4
Closed -$190 – 2481
2026
Q1 		$190 Buy
+4
New +$211 ﹤0.01% 2413
2025
Q4 		– Sell
-6
Closed -$389 – 2567
2025
Q3 		$389 Hold
6
– – ﹤0.01% 2453
2025
Q2 		$292 Hold
6
– – ﹤0.01% 2361
2025
Q1 		$204 Hold
6
– – ﹤0.01% 2419
2024
Q4 		$236 Sell
6
-3,838
-100% -$181K ﹤0.01% 2378
2024
Q3 		$208K Buy
3,844
+2,358
+159% +$120K ﹤0.01% 836
2024
Q2 		$101K Buy
1,486
+1,437
+2,933% +$83.1K ﹤0.01% 971
2024
Q1 		$3.34K Sell
49
-455
-90% -$32.6K ﹤0.01% 1713
2023
Q4 		$23K Buy
+504
New +$27.9K ﹤0.01% 1219
2023
Q3 		– Sell
-3
Closed – – 2081
2023
Q2 		$0 Sell
3
-23
-88% -$1.3K ﹤0.01% 2101
2023
Q1 		$1K Sell
26
-85
-77% -$4.13K ﹤0.01% 2130
2022
Q4 		$7K Buy
111
+98
+754% +$5.2K ﹤0.01% 1622
2022
Q3 		$1K Buy
+13
New +$942 ﹤0.01% 1902

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blue Trust Inc's CRSP Position: Q2 2026 in Review

Blue Trust Inc sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 4 shares — an estimated $190 sold.

Blue Trust Inc first reported a position in CRSP in Q3 2022 and held it in 13 quarters. The position peaked at $208K in Q3 2024. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Blue Trust Inc reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Blue Trust Inc sold 4 CRISPR Therapeutics shares in Q2 2026, an estimated $190.
  • Blue Trust Inc first reported a position in CRISPR Therapeutics in Q3 2022 and held it in 13 quarters.
  • Blue Trust Inc's CRISPR Therapeutics position peaked at $208K in Q3 2024.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Blue Trust Inc's 13F filing for Q2 2026, filed 21 Jul 2026.